1. Home
  2. WHF vs NNNN Comparison

WHF vs NNNN Comparison

Compare WHF & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo WhiteHorse Finance Inc.

WHF

WhiteHorse Finance Inc.

N/A

Current Price

$8.33

Market Cap

152.5M

Sector

Finance

ML Signal

N/A

Logo Anbio Biotechnology Class A Ordinary Shares

NNNN

Anbio Biotechnology Class A Ordinary Shares

N/A

Current Price

$3.70

Market Cap

154.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
WHF
NNNN
Founded
2011
2021
Country
United States
Germany
Employees
N/A
27
Industry
Finance Companies
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
152.5M
154.1M
IPO Year
2012
2023

Fundamental Metrics

Financial Performance
Metric
WHF
NNNN
Price
$8.33
$3.70
Analyst Decision
Hold
Analyst Count
5
0
Target Price
★ $8.13
N/A
AVG Volume (30 Days)
★ 102.4K
49.1K
Earning Date
11-09-2026
11-17-2026
Dividend Yield
★ 12.92%
N/A
EPS Growth
★ 31.91
N/A
EPS
★ 0.44
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.09
N/A
P/E Ratio
★ $18.32
$446.57
Revenue Growth
N/A
N/A
52 Week Low
$6.07
$3.09
52 Week High
$8.21
$44.73

Technical Indicators

Market Signals
Indicator
WHF
NNNN
Relative Strength Index (RSI) 64.09 30.87
Support Level $6.91 $3.09
Resistance Level N/A $6.95
Average True Range (ATR) 0.22 0.38
MACD 0.03 0.09
Stochastic Oscillator 79.41 36.52

Price Performance

Historical Comparison
WHF
NNNN

About WHF WhiteHorse Finance Inc.

WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.

About NNNN Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).

Share on Social Networks: